Due to ethical restrictions related to patient confidentiality, data are available upon request and after approval from the Sun Yat-Sen Memorial Hospital (Dr. Li-juan Wang- <wanglijuan_sysu@sina.com>).

Background {#sec005}
==========

Cervical cancer is the leading cause of cancer-related death for women in developing countries \[[@pone.0166612.ref001]\]. Because a well-organized, nation-wide screening system has not been established in most developing countries, cervical cancer always cannot be detected at an early stage or in a precancerous situation \[[@pone.0166612.ref002]\]. In fact, 70% of new cases in these countries are diagnosed at an advanced stage \[[@pone.0166612.ref003]\]. For patients with bulky early stage cervical cancer (BESCC), concurrent chemoradiotherapy (CCRT) has been the primary treatment \[[@pone.0166612.ref001]\]. Although excellent tumor control can be achieved after CCRT, impaired quality of life due to radiation-induced ovarian failure and vaginal fibrosis is significant \[[@pone.0166612.ref004]\]. Furthermore, in developing countries, radiotherapy facilities are not always readily available \[[@pone.0166612.ref005]\]. Against this background, neoadjuvant chemotherapy (NACT) combined with radical hysterectomy has been proposed as a possible alternative to CCRT. NACT can decrease tumor size, eliminate subclinical lesions and decrease the risk of lymph node metastasis thereby minimizing the need for postsurgical radiotherapy \[[@pone.0166612.ref006]--[@pone.0166612.ref009]\]. Because of these advantages, NACT is used in up to 25% of cervical cancer patients in many parts of the world such as Asia, Italy and South America \[[@pone.0166612.ref010]\].

In recent clinical studies, significant poor survival has been observed in cancer patients with elevated blood glucose levels \[[@pone.0166612.ref011]--[@pone.0166612.ref022]\]. Of these studies, three enrolled patients with cervical cancer \[[@pone.0166612.ref018], [@pone.0166612.ref019], [@pone.0166612.ref022]\]. However, patients included in these studies did not receive NACT and their baseline characteristics varied significantly with regard to tumor stage and treatment modality. Additionally, potential confounders such as obesity and dyslipidemia were not accounted for in these studies. Because there are difficulties in the interpretation of the results and no data has supported the use of plasma glucose as a prognostic factor for BESCC patients receiving NACT to date, we designed a retrospective cohort study to investigate whether elevated levels of fasting blood glucose (FBG) levels impact the prognosis of patients with BESCC.

Materials and Methods {#sec006}
=====================

Patients {#sec007}
--------

After approval from the Sun Yat-sen Memorial Hospital Institutional Review Board was obtained, we reviewed the medical records of patients who received NACT and subsequent class III radical hysterectomy for cervical cancer from our institution between January 2005 and June 2010. Inclusion criteria were as follows: histologically confirmed squamous cell carcinoma and adenocarcinoma, FIGO (Federation International of Gynecology and Obstetrics) stage IB2 and IIA2 disease, age ≥ 16 years and signed informed consent provided. Exclusion criteria were as follows: patients receiving any treatment at other institutions and patients with a history of previous chemotherapy or radiation therapy or a history of other types of malignancies. For patients included in the present study, related data were abstracted including the clinical notes, operative notes, histopathologic reports and follow-up notes.

Pretreatment evaluation consisted of a complete physical and gynecologic examination, chest radiography, pelvic ultrasonography and laboratory tests. Gynecologic examination was performed by at least two senior gynecologists. Tumors were classified according to the FIGO staging system. All cervical pathology was reviewed by at least two authorized pathologists from our institution.

All patients received 2--3 cycles of NACT, and the chemotherapeutic regimens were as follows: TP, paclitaxel + cisplatin; FP, 5-fluouracil + cisplatin; TC, paclitaxel + carboplatin; BVP, bleomycin + vincristine + cisplatin. Type III radical hysterectomy with pelvic lymphadenectomy was performed within four weeks after the last cycle of chemotherapy. Pathological responses were retrospectively evaluated and complete response (CR) was defined as no evidence of viable tumor cells on the tumorous area \[[@pone.0166612.ref023]\]. CCRT was prescribed to patients with risk factors including positive parametrium, positive lymph nodes, involved surgical margins, greater than one-third stromal invasion and lymphatic vascular space involvement \[[@pone.0166612.ref001]\]. Adjuvant chemotherapy was given at the discretion of the treating gynecologist. Blood samples were collected for laboratory tests within one week before initiation of NACT, and fasting is defined as no caloric intake for at least eight hours. FBG was measured using a glucose oxidase assay (Tosoh Corp., Tosoh, Japan). Serum triglyceride (TG), total cholesterol (CHOL), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were assessed enzymatically with commercially available reagents (Hitachi automatic biochemical analyzer model 7170, Hitachi, Tokyo, Japan). Chinese diagnosis criteria for dyslipidemia were used to classify patients into normal and abnormal groups \[[@pone.0166612.ref024]\]. Serum squamous cell carcinoma antigen (SCCA) was assessed with an immunoradiometric assay kit (Imx, Abbott Diagnostics, Abbott Park, IL, USA). A cutoff value of 3.5 ng/ml was used to stratify patients into normal and abnormal groups \[[@pone.0166612.ref025]\]. The intra-assay variation was \< 9% for all variables measured. According to American Diabetes Association (ADA) criteria, patients were classified into a euglycemic group (UG group, FBG \< 100 mg/dl) and a hyperglycemic group (HG group, FBG ≥ 100 mg/dl). Diabetes mellitus (DM) was diagnosed if FBG levels ≥ 126 mg/dl \[[@pone.0166612.ref026]\].

Patients underwent routine followed-up every 3 months for 2 years after the completion of therapy, every 6 months for the subsequent 3 years and annually thereafter. At each follow-up visit, complete history and physical examination and Papanicolaou smear of the vaginal vault were performed. Follow-up information was obtained from office visits or telephone interviews. Tumor recurrence was diagnosed by biopsy or imaging methods including positron emission tomography-computed tomography (PET-CT), magnetic resonance imaging (MRI) and computed tomography (CT).

Statistical Analyses {#sec008}
--------------------

The primary aim of the current study was to assess the influence of hyperglycemia on cancer recurrence and cancer-specific death. Recurrence-free survival (RFS) and cervical cancer-specific survival (CSS) were measured from the date of NACT until the date of events (recurrence OR death from cervical cancer) or the date of last follow-up. The Kolmogorov-Smirnov test was used to determine the distribution of continuous variables. Student's *t* test was used to compare normally distributed continuous variables, whereas the Mann-Whitney *U* test was used for data with non-normal distributions. The Chi-square test (*χ*^*2*^) or Fisher's exact test were used to analyze the frequency distribution between categorical variables where appropriate. RFS and CSS were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazard models in a forward stepwise method (conditional logistic regression) were utilized to assess the association between clinical and pathological variables and RFS and CSS. Significant variables (*P* \< 0.05) in the univariate analysis were entered into multivariate analysis. To determine independent predictors for CR, a binary logistic regression model was used and variables with significance at *P* \< 0.05 in the univariable analysis were considered as candidates in the final model. Statistical tests were two-sided and a *P* value \< 0.05 was considered to be statistically significant. All analysis was performed using IBM SPSS (version 13.0, SPSS, Chicago, IL, USA).

Results {#sec009}
=======

Characteristics of the study population {#sec010}
---------------------------------------

In total, 347 patients were included, and elevated levels of FBG were observed in 72 patients (20.7%). Clinicopathologic characteristics are summarized in [Table 1](#pone.0166612.t001){ref-type="table"}. The median FBG was 91.1 mg/dl (range: 71.4--98.2) and 110.7 mg/dl (range: 100.0--180.4) in the UG and HG groups, respectively. Of the 72 patients in the HG group, 16 (22.2%) had DM. Only 5 of these 16 (31.3%) patients were diagnosed with DM before they were referred to our institution. The HG group had significantly more women with hypertension, heart disease and lower levels of HDL, whereas the UG group had more patients achieving CR after NACT. Additionally, adjuvant chemotherapy and NACT consisting of cisplatin and paclitaxel were more frequently prescribed to UG patients.

10.1371/journal.pone.0166612.t001

###### Patient Baseline Demographic and Clinical Characteristics.
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                                             Euglycemia (n = 275)   Hyperglycemia (n = 72)   *P* value
  ------------------------------------------ ---------------------- ------------------------ -----------
  Age (years), median (range)                52 (24--80)            50 (26--72)              0.412
  Diagnosis of DM, n (%)                                                                     
      Yes                                    0                      16 (22.2)                
      No                                     0                      56 (77.8)                
  BMI (kg/m^2^), n (%)                                                                       
      \<25                                   240 (87.3)             57 (79.2)                0.081
      ≥25                                    35 (12.7)              15 (20.8)                
  Smoking, n (%)                                                                             
      Never                                  261 (94.9)             66 (91.7)                0.634
      Former                                 6 (2.2)                3 (4.2)                  
      Current                                1 (0.4)                0 (0)                    
      Missing data                           7 (2.5)                3 (4.2)                  
  Regular cervical cancer screening, n (%)                                                   
      Yes                                    14 (5.1)               9 (12.5)                 0.112
      No                                     240 (87.3)             58 (80.6)                
      Missing data                           21 (7.6)               5 (6.9)                  
  SCCA (ng/ml), n (%)                                                                        
      ≥3.5                                   162 (58.9)             39 (54.2)                0.468
      \<3.5                                  113 (41.1)             33 (45.8)                
  Stage, n (%)                                                                               
      IB2                                    142 (51.6)             34 (47.2)                0.505
      IIA2                                   133 (48.4)             38 (52.8)                
  Tumor histology, n (%)                                                                     
    SCC                                      230 (83.6)             59 (81.9)                0.732
      NSCC                                   45 (16.4)              13 (18.1)                
  Hypertension, n (%)                                                                        
      Yes                                    53 (19.3)              33 (45.8)                \<0.001
      No                                     222 (80.7)             39 (54.2)                
  Heart disease, n (%)                                                                       
      Yes                                    13 (4.7)               12 (16.7)                \<0.001
      No                                     262 (95.3)             60 (83.3)                
  CHO (mg/dl), n (%)                                                                         
      ≥200                                   124 (45.1)             38 (52.8)                0.244
      \<200                                  151 (54.9)             34 (47.2)                
  TG (mg/dl), n (%)                                                                          
      ≥150                                   50 (18.2)              19 (26.4)                0.120
      \<150                                  225 (81.8)             53 (73.6)                
  LDL-C (mg/dl), n (%)                                                                       
      ≥130                                   45 (16.4)              17 (23.6)                0.153
      \<130                                  230 (83.6)             55(76.4)                 
  HDL-C (mg/dl), n (%)                                                                       
      ≥40                                    260 (94.5)             59 (81.9)                \<0.001
      \<40                                   15 (5.5)               13 (18.1)                
  Differentiation, n (%)                                                                     
      1                                      147 (53.5)             38 (52.8)                0.540
      2                                      95 (34.5)              22 (30.6)                
      3                                      33 (12.0)              12 (16.7)                
  Deep stromal invasion, n (%)                                                               
      Yes                                    230 (83.6)             56 (77.8)                0.245
      No                                     45 (16.4)              16 (22.2)                
  LVSI, n (%)                                                                                
      Yes                                    166 (60.4)             35 (48.6)                0.072
      No                                     109 (39.6)             37 (51.4)                
  Positive margins, n (%)                                                                    
      Yes                                    9 (3.3)                5 (6.9)                  0.159
      No                                     266 (96.7)             67 (93.1)                
  Positive nodes, n (%)                                                                      
      Yes                                    108 (39.3)             28 (38.9)                0.953
      No                                     167 (60.7)             44 (61.1)                
  Positive parametrium, n (%)                                                                
      Yes                                    10 (3.6)               7 (9.7)                  0.068
      No                                     265 (96.4)             65 (90.3)                
  Adjuvant chemotherapy, n (%)                                                               
      Yes                                    71 (25.8)              10 (13.9)                0.033
      No                                     204 (74.2)             62 (86.1)                
  Post-surgical CCRT, n (%)                                                                  
      Yes                                    237 (86.2)             57 (79.2)                0.141
      No                                     38 (13.8)              15 (20.8)                
  CR achieved, n (%)                                                                         
      Yes                                    77 (28.0)              10 (13.9)                0.014
      No                                     198 (72.0)             62 (86.1)                
  NACT regimen, n (%)                                                                        
      Cisplatin+paclitaxel                   249 (90.5)             58 (80.6)                0.018
      Cisplatin-based                        26 (9.5)               14 (19.4)                

Abbreviation: BMI, body mass index; CCRT, cocurrent chemoradiotherapy; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; NSCC, non-squamous cell carcinoma; SCC, squamous cell carcinoma; SCCA, squamous cell carcinoma antigen; TG, triglyceride

Factors associated with CR after NACT {#sec011}
-------------------------------------

Given the importance of response to NACT, we conducted regression analysis to detect independent factors associated with CR after NACT. The results are summarized in [Table 2](#pone.0166612.t002){ref-type="table"}. Of the variables of interest, euglycemia before NACT, squamous cell tumor and pre-treatment SCCA levels \< 3.5 ng/ml were significantly associated with CR after NACT on univariate analysis. Furthermore, these two factors were identified as independent predictors of CR on multivariate analysis.

10.1371/journal.pone.0166612.t002

###### Univariate and Multivariate Analysis of Factors Associated with Complete Response Following Neoadjuvant Chemotherapy.
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                                          Univariate analysis   Multivariate analysis                                   
  --------------------------------------- --------------------- ----------------------- ------- ------ ---------------- -------
  Age (≥60 vs. \<60)                      0.73                  \[0.37, 1.44\]          0.359                           
  Histology (non-squamous vs. squamous)   0.36                  \[0.16, 0.82\]          0.016   0.32   \[0.14, 0.74\]   0.008
  Tumor stage (IIA2 vs IB2)               0.97                  \[0.76, 1.24\]          0.829                           
  Tumor differentiation (G3 vs. G1-2)     0.96                  \[0.47, 1.99\]          0.917                           
  FBG (\>100 mg dl/1 vs \<100 mg dl/1)    0.42                  \[0.20, 0.85\]          0.016   0.39   \[0.19, 0.81\]   0.012
  CHO (≥200mg dl/1 vs. \<200mg dl/1)      1.09                  \[0.67, 1.77\]          0.731                           
  TG (≥150 mg dl/1 vs. \<150mg dl/1)      0.97                  \[0.53, 1.79\]          0.926                           
  LDL-C (≥130 mg dl/1 vs. \<130mg dl/1)   0.67                  \[0.34, 1.33\]          0.254                           
  HDL-C (≥40 mg dl/1 vs. \<40mg dl/1)     1.00                  \[0.41, 2.43\]          0.993                           
  SCCA (≥3.5 ng/mL vs. \<3.5 ng/mL)       0.46                  \[0.28, 0.76\]          0.002   0.41   \[0.25, 0.68\]   0.001

Abbreviation: CI, confidence interval; CHO, total cholesterol; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds radio; SCCA, squamous cell carcinoma antigen; TG, triglyceride

Survival analysis {#sec012}
-----------------

The median follow-up time was 37 months (range: 4--65). Recurrence was documented in 44 (16.0%) patients in the UG group and 21 (29.2%) in the HG group, respectively. Of the 65 patients, extra-pelvic lesion was noted in 34 (52.3%) patients, pelvic lesion was noted in 19 (29.2%) patients and mixed lesion (extra-pelvic + pelvic) lesion was noted in 12 (18.5%) patients. Cancer-specific death was noted in 39 (14.2%) patients in the UG group and 22 (30.6%) patients in the HG group, respectively. Compared with the UG patients, the hazard of recurrence (univariate hazard ratio \[HR\] = 1.95, 95% CI \[1.16, 3.28\], *P* = 0.010; [Fig 1](#pone.0166612.g001){ref-type="fig"}) was significantly higher in the HG patients. To investigate whether there is a link between hyperglycemia and distant recurrence, we did an additionally analysis. We noted a trend that hyperglycemia was associated with increased risk of extra-pelvic recurrence. However, this did not reach statistical significance (HR = 1.62, 95% CI \[0.85, 3.07\]; *P* = 0.143). Compared with the UG patients, the risk of cancer-specific death (univariate HR = 2.24, 95% CI \[1.33, 3.78\], *P* = 0.002; [Fig 2](#pone.0166612.g002){ref-type="fig"}) was significantly higher in the HG patients.

![Kaplan--Meier survival curves for recurrence-free survival of cervical cancer patients receiving neoadjuvant chemotherapy for bulky early stage disease.\
The *P* values were determined by the log-rank test.](pone.0166612.g001){#pone.0166612.g001}

![Kaplan--Meier survival curves for cancer-specific survival of cervical cancer patients receiving neoadjuvant chemotherapy for bulky early stage disease.\
The *P* values were determined by the log-rank test.](pone.0166612.g002){#pone.0166612.g002}

The Cox proportional hazard model was used to identify variables that were associated with RFS ([Table 3](#pone.0166612.t003){ref-type="table"}) and CSS ([Table 4](#pone.0166612.t004){ref-type="table"}). On univariate analysis, tumor histology, lymphatic vascular space involvement (LVSI), surgical margin, lymph node involvement, parametrium invasion, CR after NACT, FBG and the utility of CCRT were significant predictors for RFS. On multivariate analysis, positive surgical margins, paramertrium invasion, node metastasis, hyperglycemia and CR were independent prognostic factors for RFS. Univariate analysis showed that tumor histology, positive nodes, positive surgical margins, positive parametrium, SCCA, hyperglycemia, utility of CCRT and CR after NACT were associated with CSS. In the multivariate model, tumor histology, CCRT and SCCA were not independently associated with CSS.

10.1371/journal.pone.0166612.t003

###### Cox Proportional Hazards Regression Models of Risk Factors Associated with Recurrece-free Survival.
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                                                                    Recurrence-free survival                                                                                                                                
  ----------------------------------------------------------------- -------------------------- ----------------- ---------- ------- ----------------- ---------- ------ ---------------- ---------- ------ ---------------- ----------
  Age (≥60 vs. \<60)                                                1.30                       \[0.71, 2.40\]    0.392      1.46    \[0.79, 2.69\]    0.230                                                                 
  BMI (kg/m^2^)                                                     1.06                       \[0.91, 1.23\]    0.474      1.07    \[0.91, 1.25\]    0.436                                                                 
  Histology (non-squamous vs. squamous)                             2.08                       \[1.21, 3.58\]    0.008      2.17    \[1.24, 3.79\]    0.007      ---    ---              ---        ---    ---              ---
  Tumor stage (IIA2 vs IB2)                                         0.92                       \[0.57, 1.50\]    0.737      1.09    \[0.85, 1.40\]    0.512                                                                 
  Tumor differentiation (G3 vs. G1-2)                               0.66                       \[0.29, 1.53\]    0.336      0.74    \[0.32, 1.72\]    0.488                                                                 
  Deep stromal invasion (yes vs. no)                                2.25                       \[0.97, 5.21\]    0.059      2.57    \[1.03, 6.42\]    0.043                                         ---    ---              ---
  LVSI (yes vs. no)                                                 1.91                       \[1.11, 3.28\]    0.020      2.01    \[1.14, 3.56\]    0.016      ---    ---              ---        ---    ---              ---
  Positive margins (yes vs. no)                                     10.70                      \[5.76, 19.89\]   \<0.0001   10.37   \[5.45, 19.75\]   \<0.0001   4.80   \[2.51, 9.18\]   \<0.0001   4.95   \[2.50, 9.80\]   \<0.0001
  Positive nodes (yes vs. no)                                       7.06                       \[3.84, 12.98\]   \<0.0001   7.17    \[3.81, 13.49\]   \<0.0001   4.54   \[2.42, 8.52\]   \<0.0001   4.42   \[2.30, 8.48\]   \<0.0001
  Positive parametrium (yes vs. no)                                 8.16                       \[4.33, 15.39\]   \<0.0001   7.81    \[4.04, 15.13\]   \<0.0001   3.13   \[1.61, 6.06\]   0.001      3.12   \[1.55, 6.28\]   0.001
  Adjuvant chemotherapy (yes vs. no)                                0.79                       \[0.43, 1.45\]    0.451      0.68    \[0.35, 1.31\]    0.248                                                                 
  CR achieved (yes vs. no)                                          0.08                       \[0.02, 0.34\]    0.001      0.09    \[0.02, 0.35\]    0.001      0.18   \[0.04, 0.77\]   0.020      0.18   \[0.04, 0.74\]   0.018
  FBG (\>100 mg/dl vs \<100 mg/dl)                                  1.95                       \[1.16, 3.28\]    0.012      2.00    \[1.14, 3.50\]    0.015      1.69   \[1.00, 2.85\]   0.050      ---    ---              ---
  CHO (≥200 mg/dl vs. \<200 mg/dl)                                  0.86                       \[0.53, 1.41\]    0.560      0.84    \[0.51, 1.40\]    0.509                                                                 
  TG (≥150 mg/dl vs. \<150 mg/dl)                                   0.89                       \[0.47, 1.66\]    0.703      0.82    \[0.42, 1.62\]    0.575                                                                 
  LDL-C (≥130 mg/dl vs. \<130 mg/dl)                                0.70                       \[0.34, 1.41\]    0.313      0.82    \[0.40, 1.66\]    0.574                                                                 
  HDL-C (≥40 mg/dl vs. \<40 mg/dl)                                  1.45                       \[0.66, 3.17\]    0.358      1.19    \[0.48, 2.96\]    0.713                                                                 
  SCCA (≥3.5 mg/dl vs. \<3.5 mg/dl)                                 1.63                       \[0.97, 2.73\]    0.067      1.60    \[0.93, 2.71\]    0.089                                                                 
  Chemotherapy regimen (Cisplatin+paclitaxel vs. cisplatin-based)   0.91                       \[0.41, 1.96\]    0.805      0.99    \[0.45, 2.18\]    0.981                                                                 
  CCRT (yes vs. no)                                                 4.10                       \[1.29, 13.06\]   0.017      5.67    \[1.39, 23.21\]   0.016      ---    ---              ---        ---    ---              ---

\* Patients with diabetes were excluded.

Abbreviation: BMI, body mass index; CCRT, cocurrent chemoradiotherapy; CI, confidence interval; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; SCCA, squamous cell carcinoma antigen; TG, triglyceride

10.1371/journal.pone.0166612.t004

###### Cox Proportional Hazards Regression Models of Risk Factors Associated with Cancer-specific Survival.
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                                                                    Cancer-specific survival                                                                                                                                   
  ----------------------------------------------------------------- -------------------------- ----------------- ---------- ------- ----------------- ---------- ------ ------------------ ---------- ------ ----------------- ----------
  Age (≥60 vs. \<60)                                                1.40                       \[0.76, 2.59\]    0.277      1.59    \[0.86, 2.90\]    0.140                                                                    
  BMI (kg/m^2^)                                                     1.04                       \[0.89, 1.21\]    0.660      1.04    \[0.88, 1.23\]    0.656                                                                    
  Histology (non-squamous vs. squamous)                             2.08                       \[1.19, 3.64\]    0.010      2.13    \[1.20, 3.81\]    0.010      ---    ---                ---        ---    ---               ---
  Tumor stage (IIA2 vs IB2)                                         1.21                       \[0.94, 1.55\]    0.150      1.28    \[0.98, 1.66\]    0.071                                                                    
  Tumor differentiation (G3 vs. G1-2)                               0.77                       \[0.33, 1.79\]    0.540      0.87    \[0.37, 2.02\]    0.746                                                                    
  Deep stromal invasion (yes vs. no)                                1.88                       \[0.85, 4.13\]    0.117      2.07    \[0.89, 4.81\]    0.093                                                                    
  LVSI (yes vs. no)                                                 1.72                       \[0.99, 2.99\]    0.053      1.81    \[1.02. 3.23\]    0.044                                           ---    ---               ---
  Positive margins (yes vs. no)                                     12.93                      \[6.80, 24.59\]   \<0.0001   12.78   \[6.54, 25.00\]   \<0.0001   5.77   \[2.93, 11.37\]    \<0.0001   5.69   \[2.90, 11.18\]   \<0.0001
  Positive nodes (yes vs. no)                                       6.07                       \[3.34, 11.05\]   \<0.0001   6.13    \[3.30, 11.41\]   \<0.0001   3.98   \[2.12, 7.46\]     \<0.0001   3.98   \[2.12, 7.46\]    \<0.0001
  Positive parametrium (yes vs. no)                                 10.23                      \[5.45, 19.22\]   \<0.0001   9.98    \[5.18, 19.23\]   \<0.0001   3.89   \[2.00, 7.57\]     \<0.0001   3.89   \[2.00, 7.57\]    \<0.0001
  Adjuvant chemotherapy (yes vs. no)                                0.74                       \[0.39, 1.39\]    0.351      0.63    \[0.32, 1.26\]    0.191                                                                    
  CR achieved (yes vs. no)                                          0.14                       \[0.04, 0.43\]    0.001      0.14    \[0.04, 0.45\]    0.001      0.30   \[0.09, 0.97\]     0.045      0.30   \[0.09, 0.97\]    0.045
  FBG (\>100 mg/dl vs \<100mg/dl)                                   2.24                       \[1.33, 3.78\]    0.003      2.31    \[1.32, 4.03\]    0.003      2.07   \[1.22, 3.51\]     0.007      2.07   \[1.22, 3.51\]    0.007
  CHO (≥200 mg/dl vs. \<200 mg/dl)                                  0.98                       \[0.59, 1.62\]    0.942      0.95    \[0.56, 1.61\]    0.854                                                                    
  TG (≥150 mg/dl vs. \<150 mg/dl)                                   1.05                       \[0.57, 1.93\]    0.887      1.00    \[0.52, 1.94\]    0.994                                                                    
  LDL-C (≥130 mg/dl vs. \<130 mg/dl)                                0.85                       \[0.43,1.66\]     0.626      1.00    \[0.50, 1.97\]    0.990                                                                    
  HDL-C (≥40 mg/dl vs. \<40 mg/dl)                                  1.56                       \[0.79, 3.43\]    0.270      1.25    \[0.50, 3.13\]    0.635                                                                    
  SCCA (≥3.5 mg/dl vs. \<3.5 mg/dl)                                 1.83                       \[1.06, 3.18\]    0.031      1.84    \[1.04, 3.25\]    0.035      ---    ---                ---        ---    ---               ---
  Chemotherapy regimen (Cisplatin+paclitaxel vs. cisplatin-based)   1.43                       \[0.72, 2.81\]    0.306      1.58    \[0.80, 3.14\]    0.186                                                                    
  CCRT (yes vs. no)                                                 3.04                       \[1.10, 8.38\]    0.032      3.69    \[1.15, 11.81\]   0.028      ---    ---                ---        ---    ---               ---

\* Patients with diabetes were excluded.

Abbreviation: BMI, body mass index; CCRT, cocurrent chemoradiotherapy; CI, confidence interval; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; SCCA, squamous cell carcinoma antigen; TG, triglyceride

A previous history of diabetes might have a great impact on outcomes, so we excluded the 16 cases with a previous history of DM and conducted sensitivity analyses ([Table 3](#pone.0166612.t003){ref-type="table"} and [Table 4](#pone.0166612.t004){ref-type="table"}). We found that hyperglycemia was associated with decreased RFS (HR = 2.00, 95% CI \[1.14, 3.50\]; *P* = 0.015) and CSS (HR = 2.31, 95% CI \[1.32, 4.03\]; *P* = 0.003). After adjustment for other variables, hyperglycemia remained an independent predictor of CSS.

Subgroup analysis for the effect of hyperglycemia {#sec013}
-------------------------------------------------

[Table 5](#pone.0166612.t005){ref-type="table"} summarizes the results of subgroup analysis. We noted that the prognostic effect of hyperglycemia remained in the subgroup analyses of age, BMI, tumor stage, tumor histology, tumor differentiation, SCCA, CHOL, TG, LDL-C, HDL-C and the NACT regimens.

10.1371/journal.pone.0166612.t005

###### Subgroup Analysis of Univariate Hazard Ratios of Survival for Hyperglycemia vs Euglycemia Using the Cox Proportional Hazard Model.

![](pone.0166612.t005){#pone.0166612.t005g}

                    Recurrence-free survival   Cancer-specific survival                                       
  ----------------- -------------------------- -------------------------- ---------- ------ ----------------- ----------
  Age                                                                                                         
      ≥60           2.49                       \[0.82, 7.62\]             0.110      2.04   \[0.66, 6.28\]    0.213
      \<60          1.82                       \[1.01, 3.28\]             0.047      2.22   \[1.23, 4.01\]    0.008
  BMI (kg/m^2^)                                                                                               
      ≥25           1.65                       \[0.47, 5.85\]             0.439      1.60   \[0.38, 6.71\]    0.523
      \<25          2.04                       \[1.15, 3.61\]             0.015      2.40   \[1.37, 4.21\]    0.002
  Stage                                                                                                       
      IB2           3.53                       \[1.74, 7.15\]             \<0.0001   3.72   \[1.71, 8.11\]    0.001
      IIA2          1.05                       \[0.47, 2.31\]             0.913      1.43   \[0.70, 2.93\]    0.323
  Tumor histology                                                                                             
      SCC           2.69                       \[1.49, 4.84\]             0.001      3.25   \[1.79, 5.91\]    \<0.0001
      NSCC          0.62                       \[0.18, 2.18\]             0.459      0.58   \[0.16, 2.06\]    0.399
  Differentiation                                                                                             
      G3            4.63                       \[0.93, 22.94\]            0.061      4.63   \[0.93, 22.94\]   0.061
      G1-2          1.75                       \[1.01, 3.05\]             0.047      2.06   \[1.18, 3.60\]    0.011
  SCCA (ng/ml)                                                                                                
      ≥3.5          2.21                       \[1.17, 4.18\]             0.014      2.40   \[1.28, 4.49\]    0.006
      \<3.5         1.72                       \[0.70, 4.27\]             0.239      2.15   \[0.83, 5.55\]    0.114
  CHO (mg/dl)                                                                                                 
      ≥200          1.73                       \[0.78, 3.81\]             0.178      1.95   \[0.90, 4.23\]    0.090
      \<200         2.19                       \[1.10, 4.36\]             0.026      2.50   \[1.23, 5.09\]    0.011
  TG (mg/ml)                                                                                                  
      ≥150          1.31                       \[0.39, 4.35\]             0.661      1.42   \[0.46, 4.34\]    0.541
      \<150         2.21                       \[1.24, 3.94\]             0.007      2.59   \[1.44, 4.69\]    0.002
  LDL-C (mg/ml)                                                                                               
      ≥130          1.44                       \[0.36, 5.75\]             0.608      1.87   \[0.53, 6.63\]    0.332
      \<130         2.13                       \[1.21, 3.73\]             0.008      2.43   \[1.37, 4.32\]    0.002
  HDL-C (mg/ml)                                                                                               
      ≥40           1.73                       \[0.97, 3.07\]             0.063      2.01   \[1.13, 3.57\]    0.017
      \<40          3.91                       \[0.75, 20.27\]            0.105      3.69   \[0.72, 19.07\]   0.119

Abbreviation: BMI, body mass index; CI, confidence interval; CHO, total cholesterol; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; NSCC, non-squamous cell carcinoma; SCC, squamous cell carcinoma; SCCA, squamous cell carcinoma antigen; TG, triglyceride

The majority of our cohort (88.5%) received TP as the NACT regimen. A further analysis was conducted to explore the prognostic value of hyperglycemia in this patient subgroup. Compared with euglycemic patients, patients with hyperglycemia had significantly higher risk of recurrence (HR = 2.10, 95% CI \[1.20, 3.67\]; *P* = 0.009) and cancer-specific death (HR = 2.07, 95% CI \[1.14, 3.74\]; *P* = 0.016).

Discussion {#sec014}
==========

Our study showed that FBG ≥ 100 mg/dl was a significant risk factor for recurrence and cancer-specific death. Positive surgical margins, positive nodes, positive parametrium and hyperglycemia were identified as independent prognostic markers for worse RFS and CSS. CR after NACT was independently associated with improved RFS and CSS. The prognostic effect of hyperglycemia remained significant in the predefined subgroup analysis. Moreover, hyperglycemic patients were less likely to achieve CR after NACT.

There are three studies evaluating the prognostic value of plasma glucose in cervical cancer patients. Despite this, none of them involved patients treated with NACT and radical surgery. Lee *et al*. analyzed 134 patients exclusively treated by radiotherapy for FIGO stage IIB-IVA cervical cancer \[[@pone.0166612.ref018]\]. They reported that patients with glucose levels ≥102 mg/dl had decreased CSS time and progression-free intervals after adjusting for other clinical factors. In the study by Rosekeila *et al*., levels of plasma glucose were observed to be significantly higher in patients with invasive cervical cancer compared with patients with benign disease (leiomyoma) and those with pre-invasive disease (cervical intraepithelial neoplasia \[CIN\] I-III) \[[@pone.0166612.ref019]\]. On the other hand, Choi *et al*. reported that hyperglycemia did not have an impact on prognosis for patients with cervical cancers \[[@pone.0166612.ref022]\]. Of concern, all patients included in their study were diagnosed with DM and this disorder was under good control at the time of diagnosis. Moreover, FBG was not considered as a potential covariate and its prognostic effect was not assessed. Therefore, in agreement with the authors' view, we believe further research is needed.

Previous research has explored the biologic mechanisms linking hyperglycemia with poor cancer outcomes and possible explanations are as follows: First, tumor cells utilize glycolysis instead of mitochondrial oxidative phosphorylation for energy production. In this setting, hyperglycemia provides a high glucose fuel source for cells to maintain rapid proliferation \[[@pone.0166612.ref027], [@pone.0166612.ref028]\]. Second, hyperglycemic conditions can result in enhanced membrane expression of glucose transporters (GLUTs) \[[@pone.0166612.ref028]\]. Because GLUTs are key mediators responsible for cellular glucose uptake, their overexpression can accelerate the process of glycolysis and increase cancer cell survival \[[@pone.0166612.ref029], [@pone.0166612.ref030]\]. Third, hyperglycemia can activate various signaling pathways and expression of genes associated with cancer cell proliferation, invasion and migration \[[@pone.0166612.ref026]\]. Furthermore, the epithelial-mesenchymal transition (EMT) phenotype, a multifaceted process critical for the acquisition of migration, invasiveness and pluripotent stem cell-like behaviors, can be induced by hyperglycemia \[[@pone.0166612.ref031]\]. Fourth, the high levels of insulin and insulin-like growth factors and chronic inflammatory status of cancer patients with hyperglycemia can inhibit apoptosis and promote metastasis. This finding has been validated by clinical studies \[[@pone.0166612.ref032]--[@pone.0166612.ref035]\].

In the present study, we observed that the rate of CR was significantly lower in hyperglycemic patients ([Table 1](#pone.0166612.t001){ref-type="table"}). Moreover, on multivariable analysis, hyperglycemia is identified as an independent predictor of CR after NACT. In fact, responsiveness to NACT has been noted as the strongest independent prognostic factor for BESCC patients \[[@pone.0166612.ref036]\]. Additionally, this finding is validated by a meta-analysis where Ye *et al*. pooled data from 18 studies and reported that the response to NACT was significantly associated with better survival outcomes \[[@pone.0166612.ref037]\]. The largest study that assessed the long-term benefits of NACT was conducted by Alessandro *et al*. where 446 patients were included and retrospectively analyzed \[[@pone.0166612.ref038]\]. Based on long-term follow-up data (median follow-up time: 12.7 years), the authors concluded that response to NACT was a reliable surrogate endpoint of survival for BESCC patients. Differences in the CR rate may be attributed to the poor response to cancer treatments among hyperglycemic patients \[[@pone.0166612.ref039]\]. Moreover, patients with hyperglycemia frequently have co-morbidities ([Table 1](#pone.0166612.t001){ref-type="table"}). Therefore, their treatment choices may be limited and even clinicians may be less likely to use aggressive treatments, which could be another possible explanation for variations in response rates and survival outcomes according to FBG levels \[[@pone.0166612.ref040], [@pone.0166612.ref041]\].

The major strengths of the present study are: (1) all patients were from a single institution, so uniform treatment principle can be ensured; (2) among studies that evaluate the prognostic role of hyperglycemia for cervical cancer patients, the current one has the largest sample size; (3) we used CSS as the primary study measure instead of overall survival. Accordingly, the possibility that worse prognosis associated with hyperglycemic status can be attributed to the hyperglycemia-related co-morbidities can be eliminated and (4) levels of FBG were measured instead of random blood glucose. Therefore, this value may be used as a baseline parameter for all patients with the same status.

Several limitations of the current study should also be acknowledged. First, due to the retrospective nature, there is unbalanced and unrecognized bias. Second, dosage and period of antidiabetic drug therapy were not documented in every patient. Accordingly, the potential impact on patient outcome cannot be clarified. Third, our findings may be specific to Chinese populations. Fourth, the proportion of patients with DM was small, which could limit the generalizability of our conclusions from a mixed sample to individual patients with different diabetic status. Finally, for patients with DM, not all clinic notes detailed whether good glycemic control was achieved and the information about treatments for hyperglycemia was not documented for most patients in the HG group. Thus, we could not analyze the survival outcomes for DM patients based on their glycemic control levels. For the same reason, effects of glucose-lowering agents such as metformin on treatment outcomes could not be evaluated. Currently, there is a growing body of evidence that metformin can lower the risk of gynecologic cancers in women with DM \[[@pone.0166612.ref042]--[@pone.0166612.ref044]\]. A recent meta-analysis also showed that metformin could be a useful adjuvant agent for cancer patients \[[@pone.0166612.ref045]\]. Given the potential anti-cancer effect, we believe randomized prospective trials are strongly warranted to further investigate metformin activity in gynecological cancers.

Conclusion {#sec015}
==========

In conclusion, our results suggest that FBG ≥ 100 mg/dl is a negative prognostic predictor for BESCC patients treated with NACT. Moreover, patients with hyperglycemia are less likely to achieve CR after NACT. These results underline the clinical utility of hyperglycemia screening, which could help physicians to identify high-risk patients and make individualized therapeutic decisions. A prospective study with adequate sample size is necessary to confirm these findings.
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